New asthma injection aims to tame overactive immune cells

This study is testing the long-term safety and effectiveness of an investigational drug called SHR-1703 for adults with a specific type of asthma driven by high levels of white blood cells called eosinophils. About 200 participants will receive regular injections under the skin for up to two years. Researchers will monitor for side effects and check if the treatment helps control asthma symptoms, reduces flare-ups, and lowers the need for other asthma medications.